Zanubrutinib
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Zanubrutinib: From B-Cell Lymphoid Malignancies to Myeloid Leukemia
One-Sentence Summary
Zanubrutinib is a selective Bruton's tyrosine kinase (BTK) inhibitor currently used for B-cell lymphoid malignancies such as CLL/SLL and Waldenström macroglobulinemia. The TxGNN model predicts it may be effective for Myeloid Leukemia, but only 2 clinical trials (neither testing zanubrutinib itself) and 9 publications (none specific to myeloid leukemia) are currently available, and the mechanistic rationale is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | B-cell lymphoid malignancies (CLL/SLL, Waldenström macroglobulinemia) — no formal Norway license record available |
| Predicted New Indication | Myeloid Leukemia |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L4 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (data gap DG002). Based on known information contained in this evidence pack, zanubrutinib is a highly selective, next-generation BTK inhibitor that blocks B-cell receptor (BCR) signaling, and its clinical benefit has been established in B-cell lymphoid malignancies (CLL/SLL, Waldenström macroglobulinemia, and other B-cell disorders).
Myeloid leukemia, however, is a myeloid-lineage rather than lymphoid-lineage malignancy, and its pathogenesis is predominantly driven by FLT3, KIT, and BCR-ABL kinase signaling — none of which are established targets of BTK inhibition. There is no recognized mechanistic overlap between the BTK/BCR pathway and myeloid leukemogenesis.
Given this, the TxGNN prediction likely reflects a broad-category over-generalization (grouping all "leukemia" subtypes together) rather than a biologically grounded signal. This assessment is reinforced by the fact that the two retrieved clinical trials test unrelated compounds (PRT2527, a CDK9 inhibitor; and CG-806/luxeptinib, a multi-kinase inhibitor) rather than zanubrutinib itself, and no literature specifically addresses zanubrutinib in myeloid leukemia.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05665530 | Phase 1 | Completed | 86 | Study of PRT2527 (a CDK9 inhibitor), evaluated as monotherapy and in combination with zanubrutinib or venetoclax, in relapsed/refractory hematologic malignancies. Relevance grade C — the investigational drug is PRT2527, not zanubrutinib; only the disease domain (hematologic malignancy) overlaps. Does not constitute direct evidence for zanubrutinib in myeloid leukemia. |
| NCT04477291 | Phase 1a/b | Terminated | 45 | Evaluated CG-806 (luxeptinib, a multi-kinase inhibitor) in relapsed/refractory AML or higher-risk MDS. Relevance grade C — different drug and mechanism than zanubrutinib; trial was terminated. Background context only. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39647999 | 2025 | RCT | J Clin Oncol | SEQUOIA 5-year follow-up: zanubrutinib vs bendamustine+rituximab in treatment-naïve CLL/SLL — supports established indication, not myeloid leukemia. |
| 40334067 | 2025 | Cohort | Blood Advances | Zanubrutinib well tolerated/effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib (BGB-3111-215 study). |
| 40829104 | 2026 | Cohort (pooled analysis) | Blood Advances | Pooled analysis (SEQUOIA/ALPINE) of zanubrutinib efficacy/safety in del(17p)/TP53-mutated CLL/SLL. |
| 36400069 | 2023 | Cohort | Lancet Haematol | Phase 2 single-arm study of zanubrutinib in BTK-inhibitor-intolerant B-cell malignancies. |
| 34959482 | 2021 | Review | Pharmaceutics | Review of tyrosine kinase inhibitors in chronic leukemias (CML, CLL) — general background, not zanubrutinib-specific myeloid data. |
| 36402930 | 2023 | Review | Leukemia | Review of BTK inhibitors (including zanubrutinib) in Waldenström macroglobulinemia management. |
| 37150651 | 2023 | Review | Clin Lymphoma Myeloma Leuk | HBV reactivation risk review in patients on BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib). |
| 38288815 | 2024 | Review | Anticancer Agents Med Chem | Synthetic chemistry review of FDA-approved anticancer drugs (2018–2021); mentions zanubrutinib only in a chemistry-synthesis context, not clinical efficacy. |
| 36325357 | 2022 | Case Report | Front Immunol | Case report of coexisting Waldenström macroglobulinemia and B-ALL — disease background only, no zanubrutinib treatment data. |
Note: None of the above literature reports zanubrutinib efficacy or safety data specifically in myeloid leukemia; all directly relevant studies pertain to its established B-cell lymphoid malignancy indications.
Norway Market Information
Zanubrutinib is currently not marketed in Norway, and no authorization records are available in this evidence pack.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (selective BTK inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA label warnings/contraindications data are currently missing — see DG001, classified as Blocking, which prevents entry into the S1 safety pre-assessment stage.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked candidate indication (myeloid leukemia, L4) lacks any clinical trial or literature evidence directly testing zanubrutinib in this disease, and the mechanistic link is biologically weak — BTK is not a recognized driver in myeloid leukemogenesis, whereas the retrieved trials/literature only test unrelated compounds or support zanubrutinib's already-established B-cell lymphoid indications. The remaining five candidates (ranks 2–6) are all L5 (pure model prediction with zero supporting evidence), and the drug is not yet marketed in Norway.
To proceed, the following is needed:
- TFDA/regulatory label data (warnings, contraindications) — currently a Blocking data gap (DG001)
- Confirmed mechanism of action documentation (DG002)
- Direct preclinical or clinical evidence linking BTK inhibition to myeloid leukemia pathophysiology, if this indication is to be pursued further
- If pursuing repurposing research, prioritize re-scoring or excluding rank 2–6 candidates given the complete absence of supporting evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.